Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23401857 | 0.84 | ALDH1A1 (0.45) | MAPK1CYP1A2CYP2C19RIPK1NPC1 | |
| SCHEMBL23400514 | 0.83 | ALDH1A1 (0.51) | MAPK1NPY5RNPC1RAB9ALMNA | |
| SCHEMBL10715419 | 0.81 | MAPK1 (0.42) | MAPK1CYP1A2CYP2C19FCGR1ANPC1 | |
| SCHEMBL31189136 | 0.80 | RAB9A (0.54) | CYP1A2CYP2C19NPC1RAB9ALMNA | |
| SCHEMBL526575 | 0.80 | RAB9A (0.54) | CYP1A2CYP2C19NPC1RAB9ALMNA | |
| SCHEMBL964125 | 0.79 | MAPK1 (0.66) | MAPK1CYP1A2CYP2C19FCGR1ANPC1 | |
| SCHEMBL23401297 | 0.78 | LMNA (0.53) | NPC1RAB9ALMNATSHRSMN1; SMN2 | |
| SCHEMBL23401870 | 0.77 | ALDH1A1 (0.46) | LMNATSHR | |
| SCHEMBL23401080 | 0.77 | ALDH1A1 (0.50) | MAPK1CYP1A2CYP2C19FCGR1ANPC1 | |
| SCHEMBL6449791 | 0.77 | LMNA (0.56) | MAPK1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-3828159-A1 | STORAGE AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-9035070-B2 | Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors | Esteve Química, S.A. (ES) | 2015-05-19 | — | — | US | disclosed |
| EP-2598469-B1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | ESTEVE QUÍMICA S A (ES) | 2014-07-23 | — | — | EP | disclosed |
| US-20130184472-A1 | Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors | ESTEVE QUIMICA, S.A. (ES) | 2013-07-18 | — | — | US | disclosed |
| EP-2418192-A1 | Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors | Esteve Química, S.A. (ES) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184472-A1 | Process for the Preparation of 1-ARYL-PYRAZOL-3-ONE Intermediates Useful in the Synthesis of SIGMA Receptors Inhibitors | SIGMAR1, OPRK1, OPRM1 | MAPK1 329/4885CYP1A2 46/4885CYP2C19 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.